Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway

Journal of Immunology

Volumn 195, Issue 8, 2015, Pages 3537-3545

  Liu, Tao ^a,b,c   Kanaoka, Yoshihide ^a,b,c   Barrett, Nora A ^a,b,c   Feng, Chunli ^b,c   Garofalo, Denise ^b,c   Lai, Juying ^b,c   Buchheit, Kathleen ^a,b,c   Bhattacharya, Neil ^a   Laidlaw, Tanya M ^a,b,c   Katz, Howard R ^a,b,c   Boyce, Joshua A ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Jeff and Penny Vinik Center for Allergic Disease Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 33; LEUKOTRIENE C4 SYNTHASE; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN SYNTHASE; IL33 PROTEIN, HUMAN; IL33 PROTEIN, MOUSE; ISOMERASE; LEUKOTRIENE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E2;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; BRONCHITIS; BRONCHOCONSTRICTION; CELL ACTIVATION; CONTROLLED STUDY; FATTY ACID SYNTHESIS; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; LOEFFLER PNEUMONIA; MALE; MAST CELL; MOUSE; NONHUMAN; NOSE POLYP; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; UPREGULATION; ADOLESCENT; ANIMAL; CLINICAL TRIAL; FEMALE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANIMALS; ASTHMA, ASPIRIN-INDUCED; DINOPROSTONE; FEMALE; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-33; INTRAMOLECULAR OXIDOREDUCTASES; LEUKOTRIENES; MALE; MAST CELLS; MICE; MICE, KNOCKOUT; MIDDLE AGED; PULMONARY EOSINOPHILIA;

EID: 84943527891     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500905     Document Type: Article

References (57)

1. Rajan, J. P., N. E. Wineinger, D. D. Stevenson, and A. A. White. 2015. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J. Allergy Clin. Immunol. 135:676-681.e1.
2. Laidlaw, T. M., and J. A. Boyce. 2013. Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol. Allergy Clin. North Am. 33:195-210.
3. Christie, P. E., P. Tagari, A. W. Ford-Hutchinson, S. Charlesson, P. Chee, J. P. Arm, and T. H. Lee. 1991. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143:1025-1029.
4. Sladek, K., and A. Szczeklik. 1993. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 6:391-399.
5. Christie, P. E., M. Schmitz-Schumann, B. W. Spur, and T. H. Lee. 1993. Airway responsiveness to leukotriene C4(LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects. Eur. Respir. J. 6:1468-1473.
6. Corrigan, C. J., R. L. Napoli, Q. Meng, C. Fang, H. Wu, K. Tochiki, V. Reay, T. H. Lee, and S. Ying. 2012. Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirinsensitive asthma. J. Allergy Clin. Immunol. 129:1636-1646.
7. Arm, J. P., S. P. O'Hickey, B. W. Spur, and T. H. Lee. 1989. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am. Rev. Respir. Dis. 140:148-153.
8. Cowburn, A. S., K. Sladek, J. Soja, L. Adamek, E. Nizankowska, A. Szczeklik, B. K. Lam, J. F. Penrose, F. K. Austen, S. T. Holgate, and A. P. Sampson. 1998. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 101:834-846.
9. Laidlaw, T. M., M. S. Kidder, N. Bhattacharyya, W. Xing, S. Shen, G. L. Milne, M. C. Castells, H. Chhay, and J. A. Boyce. 2012. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by plateletadherent leukocytes. Blood 119:3790-3798.
10. Bochenek, G., K. Nagraba, E. Nizankowska, and A. Szczeklik. 2003. A controlled study of 9alpha, 11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J. Allergy Clin. Immunol. 111:743-749.
11. Robuschi, M., G. Gambaro, P. Sestini, M. G. Pieroni, R. M. Refini, A. Vaghi, and S. Bianco. 1997. Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium. Am. J. Respir. Crit. Care Med. 155:1461-1464.
12. Yoshida, S., H. Amayasu, H. Sakamoto, K. Onuma, T. Shoji, H. Nakagawa, and T. Tajima. 1998. Cromolyn sodium prevents bronchoconstriction and urinary LTE4 excretion in aspirin-induced asthma. Ann. Allergy Asthma Immunol. 80:171-176.
13. Wenzel, S. E., J. Y. Westcott, and G. L. Larsen. 1991. Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J. Allergy Clin. Immunol. 87:540-548.
14. Wenzel, S. E., J. Y. Westcott, H. R. Smith, and G. L. Larsen. 1989. Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am. Rev. Respir. Dis. 139:450-457.
15. Wenzel, S. E., A. A. Fowler, III, and L. B. Schwartz. 1988. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am. Rev. Respir. Dis. 137:1002-1008.
16. Szczeklik, A., E. Nizankowska, and M. Duplaga, AIANE Investigators. European Network on Aspirin-Induced Asthma. 2000. Natural history of aspirininduced asthma. Eur. Respir. J. 16:432-436.
17. Johns, C. B., and T. M. Laidlaw. 2014. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am. J. Rhinol. Allergy 28:287-289.
18. Szczeklik, A., R. J. Gryglewski, G. Czerniawska-Mysik, and A. Zmuda. 1976. Aspirin-induced asthma. Hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymic preparations. J. Allergy Clin. Immunol. 58:10-18.
19. Fischer, A. R., M. A. Rosenberg, C. M. Lilly, J. C. Callery, P. Rubin, J. Cohn, M. V. White, Y. Igarashi, M. A. Kaliner, J. M. Drazen, et al. 1994. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirinsensitive asthma. J. Allergy Clin. Immunol. 94:1046-1056.
20. Kay, L. J., W. W. Yeo, and P. T. Peachell. 2006. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br. J. Pharmacol. 147:707-713.
21. Flamand, N., M. E. Surette, S. Picard, S. Bourgoin, and P. Borgeat. 2002. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol. Pharmacol. 62:250-256.
22. Yoshimura, T., M. Yoshikawa, N. Otori, S. Haruna, and H. Moriyama. 2008. Correlation between the prostaglandin D (2)/E (2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. Allergol. Int. 57:429-436.
23. Ying, S., Q. Meng, G. Scadding, A. Parikh, C. J. Corrigan, and T. H. Lee. 2006. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J. Allergy Clin. Immunol. 117:312-318.
24. Laidlaw, T. M., A. J. Cutler, M. S. Kidder, T. Liu, J. C. Cardet, H. Chhay, C. Feng, and J. A. Boyce. 2014. Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 133:1692-1701.e3.
25. Liu, T., T. M. Laidlaw, H. R. Katz, and J. A. Boyce. 2013. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc. Natl. Acad. Sci. USA 110:16987-16992.
26. Cummings, H. E., T. Liu, C. Feng, T. M. Laidlaw, P. B. Conley, Y. Kanaoka, and J. A. Boyce. 2013. Cutting edge: leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J. Immunol. 191:5807-5810.
27. Uematsu, S., M. Matsumoto, K. Takeda, and S. Akira. 2002. Lipopolysaccharide-dependent prostaglandin E (2) production is regulated by the glutathione-dependent prostaglandin E (2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J. Immunol. 168:5811-5816.
28. Kanaoka, Y., A. Maekawa, J. F. Penrose, K. F. Austen, and B. K. Lam. 2001. Attenuated zymosan-induced peritoneal vascular permeability and IgEdependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J. Biol. Chem. 276:22608-22613.
29. Lee, H. Y., C. K. Rhee, J. Y. Kang, J. H. Byun, J. Y. Choi, S. J. Kim, Y. K. Kim, S. S. Kwon, and S. Y. Lee. 2014. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma. Exp. Lung Res. 40:66-76.
30. Allakhverdi, Z., D. E. Smith, M. R. Comeau, and G. Delespesse. 2007. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 179:2051-2054.
31. Komai-Koma, M., F. Brombacher, P. N. Pushparaj, B. Arendse, C. McSharry, J. Alexander, R. Chaudhuri, N. C. Thomson, A. N. McKenzie, I. McInnes, et al. 2012. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice. Allergy 67:1118-1126.
32. Jacques, C. A., B. W. Spur, M. Johnson, and T. H. Lee. 1991. The mechanism of LTE4-induced histamine hyperresponsiveness in guinea-pig tracheal and human bronchial smooth muscle, in vitro. Br. J. Pharmacol. 104:859-866.
33. Christie, P. E., R. Hawksworth, B. W. Spur, and T. H. Lee. 1992. Effect of indomethacin on leukotriene4-induced histamine hyperresponsiveness in asthmatic subjects. Am. Rev. Respir. Dis. 146:1506-1510.
34. 2 induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig. Eur. J. Pharmacol. 669:136-142.
35. Miller, A. M. 2011. Role of IL-33 in inflammation and disease. J. Inflamm. (Lond.) 8:22.
36. Jackson, D. J., H. Makrinioti, B. M. Rana, B. W. Shamji, M. B. Trujillo-Torralbo, J. Footitt, A. G. Jerico Del-Rosario, A. Telcian, J. Nikonova, Zhu, et al. 2014. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am. J. Respir. Crit. Care Med. 190:1373-1382.
37. Snelgrove, R. J., L. G. Gregory, T. Peiró, S. Akthar, G. A. Campbell, S. A. Walker, and C. M. Lloyd. 2014. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. J. Allergy Clin. Immunol. 134:583-592.e6.
38. Hung, L. Y., I. P. Lewkowich, L. A. Dawson, J. Downey, Y. Yang, D. E. Smith, and D. R. Herbert. 2013. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc. Natl. Acad. Sci. USA 110:282-287.
39. Bartemes, K. R., K. Iijima, T. Kobayashi, G. M. Kephart, A. N. McKenzie, and H. Kita. 2012. IL-33-responsive lineage-CD25+ CD44 (hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J. Immunol. 188:1503-1513.
40. Kim, H. Y., Y. J. Chang, S. Subramanian, H. H. Lee, L. A. Albacker, P. Matangkasombut, P. B. Savage, A. N. McKenzie, D. E. Smith, J. B. Rottman, et al. 2012. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J. Allergy Clin. Immunol. 129:216-227.e1, 6.
41. Oliphant, C. J., J. L. Barlow, and A. N. McKenzie. 2011. Insights into the initiation of type 2 immune responses. Immunology 134:378-385.
42. Enoksson, M., K. Lyberg, C. Möller-Westerberg, P. G. Fallon, G. Nilsson, and C. Lunderius-Andersson. 2011. Mast cells as sensors of cell injury through IL-33 recognition. J. Immunol. 186:2523-2528.
43. Reh, D. D., Y. Wang, M. Ramanathan, Jr., and A. P. Lane. 2010. Treatmentrecalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am. J. Rhinol. Allergy 24:105-109.
44. Guo, Z., J. Wu, J. Zhao, F. Liu, Y. Chen, L. Bi, S. Liu, and L. Dong. 2014. IL-33 promotes airway remodeling and is a marker of asthma disease severity. J. Asthma 51:863-869.
45. Lefrançais, E., S. Roga, V. Gautier, A. Gonzalez-de-Peredo, B. Monsarrat, J. P. Girard, and C. Cayrol. 2012. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl. Acad. Sci. USA 109:1673-1678.
46. Lefrancais, E., A. Duval, E. Mirey, S. Roga, E. Espinosa, C. Cayrol, and J. P. Girard. 2014. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc. Natl. Acad. Sci. USA 111:15502-15507.
47. Barrett, N. A., O. M. Rahman, J. M. Fernandez, M. W. Parsons, W. Xing, K. F. Austen, and Y. Kanaoka. 2011. Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. J. Exp. Med. 208:593-604.
48. Cummings, H. E., T. Liu, C. Feng, T. M. Laidlaw, P. B. Conley, Y. Kanaoka, and J. A. Boyce. 2013. Cutting edge: leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J. Immunol. 191:5807-5810.
49. Dyer, K. D., C. M. Percopo, and H. F. Rosenberg. 2013. IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo. Immunol. Lett. 150:41-47.
50. Bessa, J., C. A. Meyer, M. C. de Vera Mudry, S. Schlicht, S. H. Smith, A. Iglesias, and J. Cote-Sierra. 2014. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J. Autoimmun. 55:33-41.
51. Arm, J. P., S. P. O'Hickey, R. J. Hawksworth, C. Y. Fong, A. E. Crea, B. W. Spur, and T. H. Lee. 1990. Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine. Am. Rev. Respir. Dis. 142:1112-1118.
52. Laitinen, A., A. Lindqvist, M. Halme, A. Altraja, and L. A. Laitinen. 2005. Leukotriene E (4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma. J. Allergy Clin. Immunol. 115:259-265.
53. Jiang, Y., L. A. Borrelli, Y. Kanaoka, B. J. Bacskai, and J. A. Boyce. 2007. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 110:3263-3270.
54. Barrett, N. A., J. M. Fernandez, A. Maekawa, W. Xing, L. Li, M. W. Parsons, K. F. Austen, and Y. Kanaoka. 2012. Cysteinyl leukotriene 2 receptor on dendritic cells negatively regulates ligand-dependent allergic pulmonary inflammation. J. Immunol. 189:4556-4565.
55. Säfholm, J., M. L. Manson, J. Bood, I. Delin, A. C. Orre, P. Bergman, M. Al-Ameri, S. E. Dahlén, and M. Adner. 2015. Prostaglandin E2 inhibits mast celldependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2015.04.002.
56. Nasser, S. M., M. Patel, G. S. Bell, and T. H. Lee. 1995. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 151:1326-1330.
57. 2: a dominant mediator of aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 135:245-252.